Published in final edited form as:

Bioorg Med Chem Lett. 2011 June 1; 21(11): 3395–3398. doi:10.1016/j.bmcl.2011.03.116.

Two methionine aminopeptidases from *Acinetobacter baumannii* are functional enzymes

Hai Yuan^a, Sergio C. Chai^a, Christopher K. Lam^b, H. Howard Xu^b, and Qi-Zhuang Ye^{a,*}

^aDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA

^bDepartment of Biological Sciences, California State University, Los Angeles, California 90032, USA

Abstract

Drug resistance in Gram-negative bacteria, such as *Acinetobacter baumannii*, is emerging as a significant healthcare problem. New antibiotics with a novel mechanism of action are urgently needed to overcome the drug resistance. Methionine aminopeptidase (MetAP) carries out an essential cotranslational methionine excision in many bacteria and is a potential target to develop such novel antibiotics. Two putative MetAP genes were identified in *A. baumannii* genome, but whether they actually function as MetAP enzymes was not known. Therefore, we established an efficient *E. coli* expression system for their production as soluble and metal-free proteins for biochemical characterization. We demonstrated that both could carry out the metal-dependent catalysis and could be activated by divalent metal ions with the order Fe(II) $\approx$ Ni(II) > Co(II) > Mn(II) for both. By using a set of metalloform-selective inhibitors discovered on other MetAP enzymes, potency and metalloform selectivity on the *A. baumannii* MetAP proteins were observed. The similarity of their catalysis and inhibition to other MetAP enzymes confirmed that both may function as competent MetAP enzymes in *A. baumannii* and either or both may serve as the potential drug target.

Keywords

metalloenzyme; drug resistance; Gram-negative bacteria; drug discovery; antibiotics; metal activation

Acinetobacter baumannii is an aerobic Gram-negative bacillus, which exists ubiquitously in nature (soil, water and animals).¹ It has emerged globally as one of the most troublesome pathogens, especially over the last 20 years.^{2,3} The bacterium can infect various parts of the body including lung, urinary tract and bloodstream and cause both community and nosocomial infections.⁴ *A. baumannii* infections have also been identified in American soldiers injured in Afghanistan and the Iraq/Kuwait region.⁵ The significant capacity of this bacterium to survive in hospital environment for a long period makes the infection even more problematic, because the transmission rate between patients is high.⁴ Treatment of infection caused by this bacterium is often difficult, because of the widespread resistance of

© 2011 Elsevier Ltd. All rights reserved.

*To whom correspondence should be addressed. Phone: 1-317-278-0304. Fax: 1-317-274-4686. yeq@iupui.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

this bacterium to most classes of antibiotics in use. Only a few “abandoned” antibiotics, such as colistin and polymyxin B, are effective, but they can also cause severe side-effects. New drugs to treat this deadly infection with a novel mechanism of action are in urgent need to overcome the drug resistance.³

Methionine aminopeptidase (MetAP) is ubiquitously found in both prokaryotic and eukaryotic cells.⁶ It is responsible for removing the *N*-terminal methionine from 50–70% of nascent proteins, which is required for localization, activation and degradation.⁶ There are two subtypes of MetAP (type 1 and type 2). Most bacteria and archaea have a single MetAP gene (either type 1 or 2), while eukaryotic cells express both type 1 and type 2 MetAP enzymes. Lethal deletion of this gene has been shown in *Escherichia coli*⁷ and *Salmonella typhimurium*.⁸ Therefore, MetAP is a potential target for developing novel antibiotics. We demonstrated that inhibitors of *E. coli* MetAP (*EcMetAP*) displayed antibacterial activity on *E. coli*, *Bacillus megaterium*, and *Bacillus subtilis*.^{9–11} Liu and colleagues also reported that inhibitors of *Mycobacterium tuberculosis* MetAPs displayed antitubercular activity,¹² and inhibitors of *Plasmodium falciparum* MetAPs displayed antimalarial activity.^{13, 14}

Multiple putative MetAP genes have been identified in a small number of bacteria, when their genomic sequences became known. For example, in genome of *A. baumannii* ATCC 17978,¹⁵ two genes for putative *A. baumannii* MetAP (*AbMetAP*) were annotated. To investigate whether they code for functional MetAP enzymes and whether the MetAPs can serve as drug targets, we cloned and expressed the two MetAP proteins from *A. baumannii* ATCC 17978 in *E. coli* and named them as *AbMetAPx* (gene locus A1S_1940) and *AbMetAPy* (gene locus A1S_2324). All bacterial MetAPs, such as *EcMetAP*, belong to type 1 MetAP that contains only a catalytic domain. Both *AbMetAPx* (264 residues) and *AbMetAPy* (275 residues) are either identical to or slightly longer than *EcMetAP* (264 residues) in length, and when the three sequences were aligned, high sequence homology was observed, with 119 identical residues (Fig. 1). Importantly, all five residues (D97, D108, H171, E204, and E235 in *EcMetAP*) for ligation to two catalytic metal ions¹⁶ are conserved in both *AbMetAPs*, as well as the catalytically critical residues C70,¹⁷ H79,¹⁸ and H178¹⁹ in *EcMetAP*. *AbMetAPy* is longer than the other two by nine residues, and an insert of six residues (GRPAFQ) is possibly located in a loop region (between P66 and K67 in *EcMetAP*), according to the structure-based sequence alignment. The existence of every key structural element for structure and function in the two *AbMetAP* sequences suggests that both may be functional MetAP enzymes.

The genes for *AbMetAPx* and *AbMetAPy* were amplified by PCR, using primers designed with ligation independent cloning (LIC) specific 5' overhangs (EMD, Gibbstown, NJ) and according to the gene sequences in *A. baumannii* ATCC 17978 genome (795 nucleotides and 828 nucleotides, respectively). The PCR fragments were cloned into pET-30 Ek/LIC vector using LIC procedures with His-tags at both N and C termini. The recombinant plasmids were transformed into *E. coli* BL21(DE3) strain for an IPTG-inducible expression. For purification of *AbMetAPx*, the *E. coli* strain was cultured in LB media, containing kanamycin, and expression of recombinant *AbMetAPx* was induced by adding IPTG. The harvested cells were lysed by passing through a French press. The supernatant of the lysate was separated on an HisTrap column. The protein was treated with Chelex-100 resin to remove divalent metal ions and concentrated to 33.5 mg/mL. *AbMetAPy* was prepared in a similar manner, except that the Chelex 100 resin treatment was replaced by EDTA. The purified *AbMetAPy* was concentrated to 11.0 mg/mL. The constructed *E. coli* expression systems produced both *AbMetAP* proteins in high yield in soluble form (65 mg *AbMetAPx* or 45 mg *AbMetAPy* per 500 mL of *E. coli* cell culture), and both were purified as metal-free preparations. Although the proteins were not analyzed for metal content after treatment with either Chelex-100 (for *AbMetAPx*) or EDTA (for *AbMetAPy*), *AbMetAPx* showed

only very weak residual activity, and *AbMetAPy* showed no detectable activity, indicating most of the metal ions were removed.

All MetAPs studied so far require divalent metal ions for catalysis as purified enzymes,¹⁶ but the actual metal ion used by MetAP in cells is largely unknown.^{9, 20} We have previously shown the importance of inhibiting the MetAP enzyme in its native metalloform for antibacterial activity⁹ and discovered MetAP inhibitors that can distinguish different metals at the enzyme active site (i.e., metalloform-selective inhibitors).^{10, 21} Therefore, we used the two metal-free *AbMetAPs* to study their activation by divalent metal ions and inhibition by a set of metalloform-selective inhibitors.

Metal ions directly participate in MetAP catalysis,²² and *EcMetAP* can be activated by Co(II), Mn(II), Fe(II), Ni(II) and Zn(II).^{23–25} To test activation of the *AbMetAP* proteins by different divalent metal ions, we used a fluorescence assay with the fluorogenic methionyl aminomethylcoumarin (Met-AMC) as the substrate.²⁶ The formation of 7-amino-4-methylcoumarin (AMC) was monitored continuously for 30 min at room temperature by fluorescence ($\lambda_{\text{ex}} = 360 \text{ nm}$, $\lambda_{\text{em}} = 460 \text{ nm}$). While no activation was observed for Zn (II) in this assay, Co(II), Mn(II), Fe(II) and Ni(II) were found to activate both *AbMetAPs*. The metal activation was instant, and the fluorescence increased linearly for at least 15 min once the metal-free proteins were mixed with the metals. Activity of *AbMetAPx* or *AbMetAPy* (both at $1 \mu\text{M}$) increased along with increasing amounts of metals until peak values were reached. Inhibition of the enzymatic activity by excessive metal ions at high concentrations was observed, which has been observed in other MetAP enzymes as well.^{25, 27, 28} For *AbMetAPx*, Ni(II) and Fe(II) were the best activators (Fig. 2A). Both Co(II) and Mn(II) showed much weaker but detectable activation. The metal activation profile of *AbMetAPy* was similar, except that Fe(II) was found to be the best, and the activation by Fe(II) required much lower metal concentration than that by Ni(II) (Fig. 2B). Using the observable activity as an indication of metal binding to the *AbMetAP* proteins, we determined the affinity of the activating metals [Co(II), Mn(II), Fe(II) and Ni(II)] to either *AbMetAPx* or *AbMetAPy* (Table 1), by monitoring the activity with increasing amounts of the metal, and calculated the K_d values.²⁹ The affinities distributed within a narrow range of $0.14 \mu\text{M}$ to $1.84 \mu\text{M}$, in a good agreement with reported affinities for *EcMetAP* [$0.3 \mu\text{M}$, $0.2 \mu\text{M}$ and $6 \mu\text{M}$ for Co(II), Fe(II) and Mn(II), respectively].^{30, 31} The K_d value for Ni(II) binding to *AbMetAPy* at $1.84 \mu\text{M}$ is significantly higher than other K_d values for the two *AbMetAP* proteins, and the weak binding is consistent with the shift of Ni(II) activation profile to higher metal concentrations for *AbMetAPy* (Fig. 2B).

Conversion of Met-AMC to fluorescent AMC is easily monitored kinetically by fluorescence, and we used this fluorescence assay to investigate the catalytic efficiencies of *AbMetAPx* and *AbMetAPy*, when they were activated by Co(II), Mn(II), Fe(II), and Ni(II). The kinetic constants k_{cat} and K_m were determined at the optimal concentration of activating metals (for *AbMetAPx*: $2.5 \mu\text{M}$ of FeCl_2 , $5 \mu\text{M}$ of NiCl_2 , $20 \mu\text{M}$ of CoCl_2 , $20 \mu\text{M}$ of MnCl_2 ; for *AbMetAPy*: $2.5 \mu\text{M}$ of FeCl_2 , $20 \mu\text{M}$ of NiCl_2 , $20 \mu\text{M}$ of CoCl_2 , $20 \mu\text{M}$ of MnCl_2) (Table 1). For *AbMetAPx*, the Ni (II)-form was the most efficient metalloform, followed by the Fe(II)-form. The Co (II) and Mn(II) forms were relatively less efficient. The efficiencies of different metalloforms of *AbMetAPy* are similar to those of *AbMetAPx*, except that the Fe(II)-form is noticeably more efficient than the Ni(II)-form. These parameters are consistent with the metal titration curves (Fig. 2).

To inhibit the growth of *A. baumannii*, it is important to know the native metal used by *AbMetAPs* in cells and to effectively inhibit *AbMetAPs* in their physiologically relevant metalloform. We have discovered unique metalloform-selective inhibitors of *EcMetAP*^{10, 21} and a *M. tuberculosis* MetAP,²⁸ and we selected a few of them and tested them on the newly

purified *AbMetAPs* for metalloform-selective inhibition. Based on our previous studies, the catechol compounds **1** and **2** were the Fe(II)-form selective, **3** and **4** were the Mn(II)-form selective, and **5–7** were the Co(II)- and Ni(II)-forms selective. When tested against *AbMetAPs*, the test compounds showed both good potency on some of the metalloforms and similar metalloform selectivity as we have observed before (Table 2).^{10, 21, 28} The metalloform-selective inhibition by these inhibitors further confirms the structural and functional similarity of the two *AbMetAPs* to other known MetAP enzymes. The similarity of their catalysis and inhibition to other MetAP enzymes confirms that both may function as competent MetAP enzymes in *A. baumannii*.

MetAP exists in every cell. *Mycoplasma genitalium* has one of the smallest genomes with only 521 genes, and MetAP gene is one of its 382 essential genes.³² The recently synthesized 1.08 Mbp *Mycoplasma mycoides* JCVI-syn1.0 genome has the MetAP gene.³³ The ubiquitous presence of this enzyme, coupled with the essential nature revealed in the gene deletion studies,^{7, 8, 34} suggests that MetAP is a potential target for discovering broad-spectrum antibacterial agents, and its novelty as a drug target may help to develop antibiotics that can overcome the current problematic drug-resistance in bacteria.

Most bacteria have only a single MetAP, but *A. baumannii* is among a small number of bacteria that have multiple MetAP genes. Two homologous MetAP isozymes in *B. subtilis* were isolated and investigated.³⁵ Although both showed enzymatic activity, only one of them was shown to be essential for growth, and the other one was concluded as non-essential for reason of low expression.³⁵ Protozoan parasite *Plasmodium falciparum* has four MetAP proteins, and inhibitors were discovered and characterized on one of the four and showed antimalarial activity.¹³ Therefore, although both *AbMetAPx* and *AbMetAPy* are competent MetAP enzymes, their relative biological significance in *A. baumannii* remains to be elucidated, and either or both may serve as the drug target.

Bacterial MetAPs, including *AbMetAPx* and *AbMetAPy*, are also homologous to human type 1 MetAP, and to a lesser extent, to human type 2 MetAP. Because of the significant role of human MetAPs in cell proliferation and angiogenesis,^{36, 37} potentially, antibacterial MetAP inhibitors may exhibit toxicity due to inhibition of human MetAPs. However, the redundant human MetAPs have overlapping substrate specificity,³⁸ which may alleviate some of the potential toxicity of *AbMetAP* inhibitors. In addition, *EcMetAP* was found to use Fe(II) as the native cofactor,⁹ and other bacterial MetAPs may use Fe(II), too, due to its availability. On the other hand, Fe(II) is tightly regulated in mammalian cellular environment. The ability for human hosts to sequester iron is a defense mechanism against bacterial infection, and the amount of free iron (10^{-18} M) is well below the levels required to support the growth of most bacteria (10^{-6} to 10^{-7} M).^{39, 40} It was reported that human type 2 MetAP uses Mn(II) as its physiological metal,²⁰ and the native metal for human type 1 MetAP is currently unknown but could be Mn(II) due to the low Fe(II) abundance. Therefore, our metalloform-selective inhibitors, especially the Fe(II)-form selective inhibitors, could be the promising leads with such selectivity for bacterial MetAPs.

Abbreviations

MetAP	methionine aminopeptidase
<i>AbMetAP</i>	<i>A. baumannii</i> methionine aminopeptidase
<i>EcMetAP</i>	<i>E. coli</i> methionine aminopeptidase
Met-AMC	methionyl aminomethylcoumarin

Acknowledgments

This work was supported by National Institutes of Health Grants R01 AI065898 and R56 AI065898 (to Q.-Z.Y.), and SC3 GM083686 (to H. H. X.). Additional support was from Indiana University School of Medicine (BRG) and Indiana University and Purdue University at Indianapolis (RSFG).

References and notes

1. Bassetti M, Righi E, Esposito S, Petrosillo N, Nicolini L. *Future Microbiol.* 2008; 3:649. [PubMed: 19072182]
2. Peleg AY, Seifert H, Paterson DL. *Clinical microbiology reviews.* 2008; 21:538. [PubMed: 18625687]
3. Fischbach MA, Walsh CT. *Science.* 2009; 325:1089. [PubMed: 19713519]
4. Bergogne-Berezin E, Towner KJ. *Clinical microbiology reviews.* 1996; 9:148. [PubMed: 8964033]
5. Fournier PE, Richet H. *Clin Infect Dis.* 2006; 42:692. [PubMed: 16447117]
6. Giglione C, Boularot A, Meinel T. *Cell Mol Life Sci.* 2004; 61:1455. [PubMed: 15197470]
7. Chang SY, McGary EC, Chang S. *J Bacteriol.* 1989; 171:4071. [PubMed: 2544569]
8. Miller CG, Kukral AM, Miller JL, Movva NR. *J Bacteriol.* 1989; 171:5215. [PubMed: 2670909]
9. Chai SC, Wang WL, Ye QZ. *J Biol Chem.* 2008; 283:26879. [PubMed: 18669631]
10. Wang WL, Chai SC, Huang M, He HZ, Hurley TD, Ye QZ. *J Med Chem.* 2008; 51:6110. [PubMed: 18785729]
11. Wang WL, Chai SC, Ye QZ. *Bioorg Med Chem Lett.* 2009; 19:1080. [PubMed: 19167218]
12. Olaleye O, Raghunand TR, Bhat S, He J, Tyagi S, Lamichhane G, Gu P, Zhou J, Zhang Y, Grosset J, Bishai WR, Liu JO. *Chem Biol.* 2010; 17:86. [PubMed: 20142044]
13. Chen X, Chong CR, Shi L, Yoshimoto T, Sullivan DJ Jr, Liu JO. *Proc Natl Acad Sci U S A.* 2006; 103:14548. [PubMed: 16983082]
14. Chen X, Xie S, Bhat S, Kumar N, Shapiro TA, Liu JO. *Chem Biol.* 2009; 16:193. [PubMed: 19246010]
15. Smith MG, Gianoulis TA, Pukatzki S, Mekalanos JJ, Ornston LN, Gerstein M, Snyder M. *Genes & development.* 2007; 21:601. [PubMed: 17344419]
16. Lowther WT, Matthews BW. *Biochim Biophys Acta.* 2000; 1477:157. [PubMed: 10708856]
17. Li JY, Cui YM, Chen LL, Gu M, Li J, Nan FJ, Ye QZ. *J Biol Chem.* 2004; 279:21128. [PubMed: 14976199]
18. Watterson SJ, Mitra S, Swierczek SI, Bennett B, Holz RC. *Biochemistry.* 2008; 47:11885. [PubMed: 18855426]
19. Copik AJ, Swierczek SI, Lowther WT, D'Souza VM, Matthews BW, Holz RC. *Biochemistry.* 2003; 42:6283. [PubMed: 12755633]
20. Wang J, Sheppard GS, Lou P, Kawai M, Park C, Egan DA, Schneider A, Bouska J, Lesniewski R, Henkin J. *Biochemistry.* 2003; 42:5035. [PubMed: 12718546]
21. Ye QZ, Xie SX, Huang M, Huang WJ, Lu JP, Ma ZQ. *J Am Chem Soc.* 2004; 126:13940. [PubMed: 15506752]
22. Lowther WT, Orville AM, Madden DT, Lim S, Rich DH, Matthews BW. *Biochemistry.* 1999; 38:7678. [PubMed: 10387007]
23. Walker KW, Bradshaw RA. *Protein Sci.* 1998; 7:2684. [PubMed: 9865965]
24. D'Souza VM, Holz RC. *Biochemistry.* 1999; 38:11079. [PubMed: 10460163]
25. Li JY, Chen LL, Cui YM, Luo QL, Li J, Nan FJ, Ye QZ. *Biochem Biophys Res Commun.* 2003; 307:172. [PubMed: 12849997]
26. Yang G, Kirkpatrick RB, Ho T, Zhang GF, Liang PH, Johanson KO, Casper DJ, Doyle ML, Marino JP Jr, Thompson SK, Chen W, Tew DG, Meek TD. *Biochemistry.* 2001; 40:10645. [PubMed: 11524009]
27. Lu JP, Ye QZ. *Bioorg Med Chem Lett.* 2010; 20:2776. [PubMed: 20363127]
28. Lu JP, Chai SC, Ye QZ. *J Med Chem.* 2010; 53:1329. [PubMed: 20038112]

29. Chai SC, Lu JP, Ye QZ. *Anal Biochem.* 2009; 395:263. [PubMed: 19712663]
30. D'Souza VM, Bennett B, Copik AJ, Holz RC. *Biochemistry.* 2000; 39:3817. [PubMed: 10736182]
31. D'Souza VM, Swierczek SI, Cospier NJ, Meng L, Ruebush S, Copik AJ, Scott RA, Holz RC. *Biochemistry.* 2002; 41:13096. [PubMed: 12390038]
32. Glass JI, Assad-Garcia N, Alperovich N, Yooseph S, Lewis MR, Maruf M, Hutchison CA 3rd, Smith HO, Venter JC. *Proc Natl Acad Sci U S A.* 2006; 103:425. [PubMed: 16407165]
33. Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, Benders GA, Montague MG, Ma L, Moodie MM, Merryman C, Vashee S, Krishnakumar R, Assad-Garcia N, Andrews-Pfannkoch C, Denisova EA, Young L, Qi ZQ, Segall-Shapiro TH, Calvey CH, Parmar PP, Hutchison CA 3rd, Smith HO, Venter JC. *Science.* 2010; 329:52. [PubMed: 20488990]
34. Li X, Chang YH. *Proc Natl Acad Sci U S A.* 1995; 92:12357. [PubMed: 8618900]
35. You C, Lu H, Sekowska A, Fang G, Wang Y, Gilles AM, Danchin A. *BMC Microbiol.* 2005; 5:57. [PubMed: 16207374]
36. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. *Proc Natl Acad Sci U S A.* 1997; 94:6099. [PubMed: 9177176]
37. Towbin H, Bair KW, DeCaprio JA, Eck MJ, Kim S, Kinder FR, Morollo A, Mueller DR, Schindler P, Song HK, van Oostrum J, Versace RW, Voshol H, Wood J, Zabludoff S, Phillips PE. *J Biol Chem.* 2003; 278:52964. [PubMed: 14534293]
38. Xiao Q, Zhang F, Nacev BA, Liu JO, Pei D. *Biochemistry.* 2010; 49:5588. [PubMed: 20521764]
39. Payne SM. *Trends Microbiol.* 1993; 1:66. [PubMed: 8044465]
40. Wooldridge KG, Williams PH. *FEMS Microbiol Rev.* 1993; 12:325. [PubMed: 8268005]

Figure 1. Sequence alignment between *EcMetAP*, *AbMetAPx* and *AbMetAPy*

The secondary structures (H, helix; S, sheet) are based on our *EcMetAP* structure (1XNZ) ²¹ and shown above the sequences. Identical residues are shaded, and the five conserved metal-coordinating residues are in bold face and underlined.

Figure 2. Activation of *AbMetAPx* (A) and *AbMetAPy* (B) by divalent metals
Co(II), closed squares; Mn(II), open squares; Fe(II), closed diamonds; and Ni(II), open diamonds.

Table 1

Binding and kinetic parameters of AbMetAPx and AbMetAPy ^a

	AbMetAPx				AbMetAPy			
	Co(II)	Mn(II)	Fe(II)	Ni(II)	Co(II)	Mn(II)	Fe(II)	Ni(II)
K_d , μM	0.45	0.57	0.14	0.26	0.39	0.33	0.54	1.84
K_m , μM	168	154	155	111	130	115	161	144
k_{cat} , $\text{s}^{-1} \times 10^4$	1.59	0.508	2.63	3.05	1.37	0.550	4.49	3.12
k_{cat}/K_m , $\text{M}^{-1}\text{s}^{-1}$	0.948	0.330	1.70	2.75	1.05	0.479	2.78	2.17

^a K_d is the dissociation constant. K_m and k_{cat} are the Michaelis–Menten constants.

Table 2

Inhibition of *AbMetAPx* and *AbMetAPy* by metalloform-selective inhibitors ^a

Compounds	<i>AbMetAPx</i>				<i>AbMetAPy</i>			
	Co(II)	Mn(II)	Fe(II)	Ni(II)	Co(II)	Mn(II)	Fe(II)	Ni(II)
1	39	79	32	72	24	34	0.95	56
2	33	22	0.65	27	21	30	0.51	55
3	494	7.1	>500	251	>500	6.1	355	286
4	394	13	358	188	381	0.92	288	186
5	0.88	303	>500	23	0.64	34	>500	2.2
6	2.1	145	>500	44	3.8	103	>500	4.4
7	0.78	64	128	4.9	0.38	14	94	0.40

^a IC₅₀ values are expressed in μM.

^b Purified metal-free *AbMetAP* proteins were activated by the metals at the optimal activation concentration [for *AbMetAPx*: 2.5 μM Fe(II), 5 μM Ni(II), 20 μM Co(II) or Mn(II); for *AbMetAPy*: 2.5 μM Fe(II); 20 μM Co(II), Ni(II) or Mn(II)].